Cardiac Biotech Solutions Inc.
Cardiac Biotech Solutions Inc.
Your view on CBSC
Overview
What the company does, where it operates, and who runs it.
About Cardiac Biotech Solutions Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Charles K. Martin
- Headquarters
- 340 State Place, Las Vegas, CA, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Charles K. Martin
- Headquarters
- 340 State Place, Las Vegas, CA, US
Cardiac Biotech Solutions Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space.
Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
Cardiac Biotech Solutions' wholly owned U.S. subsidiary, My-Cardia (USA), Inc., develops ECG recording device worn by patients in an ambulatory setting for up to 30 days.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Cardiac Biotech Solutions Inc., and the rating behind it. CBSC last traded at $0.06; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cardiac Biotech Solutions Inc.. Starting points for Cardiac Biotech Solutions Inc.: EPS -$0.0051, beta 1.82 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cardiac Biotech Solutions Inc.. Cardiac Biotech Solutions Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cardiac Biotech Solutions Inc.. Trailing twelve-month EPS for Cardiac Biotech Solutions Inc. stands at -$0.0051. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cardiac Biotech Solutions Inc.. Cardiac Biotech Solutions Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cardiac Biotech Solutions Inc. valued side by side against its closest peers. Cardiac Biotech Solutions Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Cardiac Biotech Solutions Inc., and how their positions are changing. At a $6.6M market value, institutional positions materially move Cardiac Biotech Solutions Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Cardiac Biotech Solutions Inc. executives and directors. Shares of Cardiac Biotech Solutions Inc. have traded between $0.02 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cardiac Biotech Solutions Inc.. Cardiac Biotech Solutions Inc. is a $6.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cardiac Biotech Solutions Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cardiac Biotech Solutions Inc.. Coverage tracks Cardiac Biotech Solutions Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.